• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Blend Therapeutics

edit

Blend is discovering and developing integrative combination medicines with the unprecedented ability to precisely control each agent’s therapeutic action in concert. Using their proprietary Maestro™ platform, they design and integrate drugs to target distinct disease pathways with optimal efficacy and safety. Blend was founded by three leaders in the fields of chemistry and nanomedicine from MIT and Harvard Medical School: Dr. Robert Langer and Dr. Stephen Lippard of MIT, and Dr. Omid Farokhzad of Harvard Medical School.

Recent Milestones

edit

• 
  Blend Therapeutics received $16M in Series B funding. (12/17/12)
  Posted 12/19/12 at 3:51am via yahoo.com
• 
  Blend Therapeutics received $2.8M in Series A funding. (1/6/12)
  Posted 1/8/12 at 8:00pm via biocentury.com

Videos

Screenshots

edit

Above: Blend Therapeutics
Uploaded: 1/9/12

Sources

1. Blend debuts with $2.8 million (biocentury.com) [edit]
2. Blend Therapeutics Closes $16 Million in Series B Financing (finance.yahoo.com) [edit]